Company Overview
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.
Why Investors Should Care
Net profit has compounded at 34.4% per year over the last five years.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR 34.4%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | 34.40% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +148.08% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | - |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- RSI (14)89.78 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 34.4% over 5 years.
CONS
- RSI at 90 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VOGX Vogenx, Inc. PHARMA | 32.25 | -293.18 | $479.08M | 0.00% | - | - | - | 34.40% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 372.20K | 463.15K |
| Operating Income | -372.20K | -463.15K |
| EBITDA | -372.20K | -463.15K |
| Interest Expense | - | - |
| Pretax Income | -356.62K | -475.45K |
| Tax Provision | - | - |
| Net Income | -356.62K | -475.45K |
| Diluted EPS | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 2.30M | 1.44M |
| Operating Income | -2.30M | -1.44M |
| EBITDA | -2.30M | -1.44M |
| Interest Expense | - | - |
| Pretax Income | -2.20M | -1.45M |
| Tax Provision | - | - |
| Net Income | -2.20M | -1.45M |
| Diluted EPS | -0.29 | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VOGX
Vogenx (VOGX) Stock Forecast and Price Target 2026 - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTFAzdm5UR1gzNFZwd1VFazhnRzlWdGVqQTk2RElXR0NWUDFETzBrei01bzluOTM1NUNyNXF3MWY2WXNoVkZpTUdsVktUSVNZZTlSZzZ3MThNZXFvN0pwbzlGWFU0bndCZw?oc=5" target="_blank">Vogenx (VOGX) Stock Forecast …
Analysts Offer Insights on NA Companies: SpaceX (SPCX) and Vogenx, Inc. (VOGX) - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxQZ2NXcHJYbHhqc241dzRQOXNWNFhOU0ZQUWZaYzEwWjJLWDljRlZaNW5HRU0yd2NqRXAxQ3NqX2lROUVDeVowQXphOGZiTDExaXkya3ptUTZEM3c1eG1mV053VzRJVUVMQzRxd1l5OUNvUUZIY1NpQ0VhbEt3bHJQUXo2cFdieExiUUpKVX…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE5vMW96M1RDdW4zTmFWRUxnbDZndmFDeXpiRVluRzdrbGxnQk52WldCek90TWh5amxheEhEMXJOWDA2M3Z5VHpwcXlQaWMxMVdP?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Vogenx (VOGX) director details $0.93–$1.20 stock options - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNUHRreVFXX3VCQnNkazR2RU11SDE2N1VwY2pyUlpvMFN0WmZwTDYwTHRCZGlyZnNhUk1zNU5fWVBBTjg0NTFsNm1sR25ZTndQeWZQX3ZHcTVhbEZoTkluTW82RGRIaW5xcnc0T0RBU1JQWG1BYVhWbS1zS3JidWNMSjgzLWxaZ0d5VVBROX…
Vogenx (VOGX) Analyst Ratings, Stock Forecast and Price Target - Moomoo
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE5DU28yQUFjV1hUSE5uM0doMWVOSEw0VGdzUDJ3b1RMUGVvRlJyRC1sSXNwczJFMEEtc2ZHaHV1OE02QnJsYVFzS0FFWGtmMEZSMlhzc1NJYzU?oc=5" target="_blank">Vogenx (VOGX) Analyst Ratings, Stock Forecast an…
Live stock, index, futures, Forex and Bitcoin charts on TradingView - TradingView
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE1sdTlwQmQ0SDNpMThCYkFDWE9rUmdGR2QxVm8wNkhxRVRraE9LdVlTUHRLZktNYzlUZTNxXzZVcnAySEJoZ2xEc1pmMm0wR2kweGgxUWxZNFBHNmZLdDRiUzRodkdBbUg4Z0FOd0p3R3lpUHhlbUhScnNiT29MUQ?oc=5" target="_blan…
VOGX — Frequently Asked Questions
What is the current share price of Vogenx, Inc. (VOGX)?
As of 2026-09-07 16:24 PDT, Vogenx, Inc. (VOGX) trades at $32.25 on NasdaqCM. Its 52-week range is $13.00 to $34.00.
What is the market capitalisation of VOGX?
Vogenx, Inc. (VOGX) has a market capitalisation of $479.08M on NasdaqCM.
What is the P/E ratio of VOGX?
VOGX trades at a trailing price-to-earnings (P/E) ratio of -293.18. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -126.58.
Is VOGX a good stock to buy?
This page provides a data-driven analysis of Vogenx, Inc. (VOGX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.